Soligenix, Inc. (SNGX)

NASDAQ: SNGX · IEX Real-Time Price · USD
0.637 -0.009 (-1.41%)
Jan 18, 2022 3:07 PM EST - Market open
Market Cap27.31M
Revenue (ttm)869,409
Net Income (ttm)-13.39M
Shares Out42.87M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume138,809
Open0.650
Previous Close0.646
Day's Range0.620 - 0.664
52-Week Range0.600 - 2.480
Beta1.15
AnalystsStrong Buy
Price Target4.88 (+666.1%)
Earnings DateNov 11, 2021

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This se...

IndustryBiotechnology
IPO DateJun 15, 1987
CEOChristopher Schaber
Employees17
Stock ExchangeNASDAQ
Ticker SymbolSNGX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Soligenix stock is "Strong Buy" and the 12-month stock price forecast is 4.88.

Price Target
$4.88
(666.09% upside)
Analyst Consensus: Strong Buy

News

Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good ne...

6 days ago - Newsfile Corp

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts

PRINCETON, N.J., Jan. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

1 week ago - PRNewsWire

Soligenix to Present at Upcoming Investor Conferences

PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 week ago - PRNewsWire

Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies

PRINCETON, N.J., Jan. 4, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 weeks ago - PRNewsWire

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine

PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 month ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results

PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

2 months ago - PRNewsWire

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom

PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine

PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022

In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the c...

2 months ago - Benzinga

Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and...

PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

2 months ago - PRNewsWire

Highlights and Insights into Soligenix

Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized VaccinesNew York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biote...

3 months ago - Newsfile Corp

HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorde...

PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

3 months ago - PRNewsWire

Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic

COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta VariantsNew York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and ad...

3 months ago - Newsfile Corp

Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Va...

PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference

PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

3 months ago - PRNewsWire

Soligenix To Test Synthetic Hypericin In Psoriasis Patients

Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Relat...

4 months ago - Benzinga

Soligenix to Advance Synthetic Hypericin Development in Psoriasis

PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

4 months ago - PRNewsWire

Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics

Soligenix discusses its contribution to addressing future serious public health threats in a podcastNew York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has a...

4 months ago - Newsfile Corp

SNGX Stock: The Big FDA News Giving Biotech Penny Stock Soligenix a Boost

Soligenix (SNGX) stock is roaring higher on Thursday thanks to some positive news from the U.S. Food and Drug Administration today. The post SNGX Stock: The Big FDA News Giving Biotech Penny Stock Solig...

4 months ago - InvestorPlace

Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate

The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. "T...

4 months ago - Benzinga

FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma

PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

4 months ago - PRNewsWire

Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen condit...

4 months ago - PRNewsWire

Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Plat...

PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

4 months ago - PRNewsWire

Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates

Soligenix Inc (NASDAQ: SNGX) announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform presentation. Data from ...

5 months ago - Benzinga

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates

PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

5 months ago - PRNewsWire